Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03675308) enrolled 964 people — 481 in the placebo group and 483 in the risankizumab group. The vast majority completed the study (467 and 473 respectively). The trial was measuring outcomes in people with psoriatic arthritis, a condition involving joint inflammation and skin psoriasis. The main thing researchers were tracking at 24 weeks was whether participants reached a standardised level of joint improvement, known as an "ACR20 response" — meaning at least a 20% improvement in tender joints, swollen joints, and several other measures of disease activity assessed by both doctors and patients. The reported data shows that at the 24-week mark, 57.3% of participants in the risankizumab group met the ACR20 joint improvement threshold, compared with 33.5% in the placebo group. A similar pattern was reported at 16 weeks (56.3% versus 33.4%). For the skin-related measure (PASI 90 — at least a 90% reduction in the area and severity of psoriasis), the reported figures were 52.3% for risankizumab and 9.9% for placebo. Regarding "minimal disease activity" — a state where most signs of the disease are at very low levels — 25.0% of the risankizumab group and 10.2% of the placebo group met that threshold at week 24. The reported data also shows changes in disability and nail psoriasis scores. On the disability questionnaire (scored 0–3, where lower is better), the risankizumab group showed an average change of −0.31 from their starting score, compared with −0.11 in the placebo group — with a negative number indicating improvement. For nail psoriasis severity (scored 0–130, lower being better), the average change was −9.76 in the risankizumab group versus −5.57 in the placebo group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 34911706) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Psoriatic Arthritis Trial, Active, Not Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Psoriatic Arthritis (PsA) with symptoms that started at least 6 months before your screening appointment, and you meet the standard classification criteria for PsA.
- You have active disease at the start of the trial, meaning at least 5 joints that are tender and at least 5 joints that are swollen.
- You have active plaque psoriasis with at least one skin patch that is 2 cm or larger, or you have nail changes caused by psoriasis.
- You have either not responded well enough to, could not tolerate, or cannot take traditional disease-modifying arthritis medications (such as methotrexate or sulfasalazine).
- You have either at least one sign of joint damage visible on an X-ray, or a blood test showing elevated levels of a protein linked to inflammation (hsCRP of 3.0 mg/L or higher).
Who may not be able to join:
- The trial doctor has decided, for any reason, that you would not be a suitable candidate for the study.
- You have a known allergy or sensitivity to the study drug, risankizumab.
- You have previously been treated with a biologic medication (a type of advanced medication made from living cells, often given by injection or infusion).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.